USMLE Step 1 practice question: Basal cell carcinoma: hedgehog pathway and Smoothened inhibitors
USMLE Step 1DermatologyPathology
This agent most likely inhibits which of the following proteins?
- BRAF, a serine-threonine kinase in the MAPK signaling cascade
- Frizzled, a receptor that stabilizes beta-catenin in Wnt signaling
- mTOR, a kinase that promotes protein synthesis downstream of PI3K-AKT
- Smoothened, a transmembrane protein normally repressed by Patched
- Janus kinase 2, which phosphorylates STAT proteins after cytokine binding
Show answer and explanation
Correct answer: D. Smoothened, a transmembrane protein normally repressed by Patched
A pearly, rolled-border plaque with arborizing telangiectasias and central ulceration on sun-exposed facial skin, with nests of basaloid cells showing peripheral palisading and retraction clefts, is basal cell carcinoma (BCC). BCC is the most common skin cancer; it rarely metastasizes but can be locally destructive, as with this orbital invasion.
Nearly all BCCs have constitutive activation of the Hedgehog signaling pathway. Normally, the Patched 1 receptor (PTCH1) represses Smoothened (SMO), a 7-transmembrane signal transducer. When a Hedgehog ligand binds PTCH1, this repression is relieved, and SMO activates GLI transcription factors that drive proliferation genes. In most sporadic BCCs, PTCH1 is inactivated by mutation (often with a UV-signature pattern); fewer tumors carry activating SMO mutations. Germline PTCH1 mutations cause nevoid basal cell carcinoma (Gorlin) syndrome, with many BCCs from a young age, odontogenic keratocysts of the jaw, palmar pits and medulloblastoma.
Because the pathway is activated at the level of SMO or above it, the oral SMO inhibitors vismodegib and sonidegib are used for locally advanced BCC not amenable to surgery or radiation and for metastatic BCC. Adverse effects reflect Hedgehog signaling in normal tissues: muscle spasms, dysgeusia, alopecia, weight loss and fatigue; the drugs are teratogenic. The PD-1 inhibitor cemiplimab is an option after Hedgehog inhibitor failure or intolerance.
Why the other options are wrong
- A. BRAF, a serine-threonine kinase in the MAPK signaling cascade — BRAF V600E inhibitors such as vemurafenib and dabrafenib treat melanoma; the MAPK pathway is not the main driver of basal cell carcinoma.
- B. Frizzled, a receptor that stabilizes beta-catenin in Wnt signaling — Frizzled receptors bind Wnt ligands; Wnt-beta-catenin activation characterizes colorectal cancer with APC loss, not basal cell carcinoma.
- C. mTOR, a kinase that promotes protein synthesis downstream of PI3K-AKT — mTOR inhibitors such as everolimus are used in renal cell carcinoma and tuberous sclerosis complex, not as targeted therapy for basal cell carcinoma.
- E. Janus kinase 2, which phosphorylates STAT proteins after cytokine binding — JAK2 inhibitors such as ruxolitinib treat myeloproliferative neoplasms with JAK2 V617F, not basal cell carcinoma.
Key point
Basal cell carcinoma is driven by Hedgehog pathway activation, usually from loss of PTCH1, and locally advanced disease is treated with Smoothened inhibitors such as vismodegib.
Memory hook
Patched is the brake, Smoothened the accelerator: BCC loses the brake, so vismodegib takes the foot off the gas.
15 free bank questions a day, exam-length timed blocks, spaced repetition and 3D anatomy — in English and Russian.
Play free